Compare Johnson & Johnson (JNJ) vs ThredUp Inc (TDUP) Price & Performance

Johnson & Johnson (JNJ) trades at $249.58, down 1.37% today, amid a generally bullish technical outlook with strong moving average signals. The company reported robust Q2 2026 earnings, beating EPS estimates and raising full-year guidance, with revenue growth to $94.19B in 2025 and a net income margin of 21.48%. Recent news highlights strong institutional interest and positive analyst sentiment, though the stock faces pressure from MedTech segment misses despite overall strength.

The outlook for JNJ remains positive, supported by solid fundamentals, a consistent dividend history, and upward revised earnings guidance. Key risks include competitive pressures in pharmaceuticals, regulatory hurdles, and execution challenges in the MedTech division. With a consensus price target of $279.33, representing ~12% upside, the stock offers a compelling opportunity for long-term investors, balanced by sector-specific volatility and macroeconomic factors.

TDUP trades at $6.57, down 0.45% today, with a bullish technical signal from moving averages but neutral oscillators. The company reported Q1 2026 revenue growth of 15% year-over-year to $81.7 million, though it missed EPS expectations. Analyst consensus is bullish with a $6.90 price target, and recent news highlights AI integration and a new peer-to-peer marketplace launch.

The outlook is cautiously optimistic due to strong revenue growth and improving gross margins, but persistent net losses and negative ROE pose risks. Upside potential exists if profitability improves, yet investors face execution and competitive threats in the resale market.